title: Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
abstract: Trabectedin is the first marine-derived anti-neoplastic drug approved for the treatment of advanced soft tissue sarcoma and, in combination with pegylated liposomal doxorubicin, for the treatment of patients with relapsed platinum-sensitive ovarian cancer. From the beginning of its development, trabectedin showed some peculiar properties that clearly distinguished it from other anti-cancer drugs. In this mini-review, we will outline the current state of knowledge regarding the mode of action of trabectedin, which appears to represent a new class of anti-neoplastic drugs acting both on cancer cells and on the tumour microenvironment.
authors.affiliation: Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: D'Incalci
authors.affiliation: Pharma Mar S.A., Madrid, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Badri
authors.affiliation: Pharma Mar S.A., Madrid, Spain.
authors.forename: C M
authors.initials: CM
authors.lastname: Galmarini
authors.affiliation: Department of Immunology and Inflammation, IRCCS-Clinical and Research Institute Humanitas, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Allavena
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology* / Q000627:therapeutic use; D004149:Dioxoles / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D018208:Liposarcoma, Myxoid / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D044005:Tetrahydroisoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D000077606:Trabectedin; D014178:Translocation, Genetic; D059016:Tumor Microenvironment / Q000187:drug effects*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4
references.pmid: 10841573
references.citation: Gynecol Oncol. 2013 Sep;130(3):505-10
references.pmid: 23774301
references.citation: Ann Oncol. 2009 Aug;20(8):1439-44
references.pmid: 19465423
references.citation: Eur J Cancer. 2001 Jan;37(1):97-105
references.pmid: 11165136
references.citation: Mol Cancer Ther. 2009 Feb;8(2):449-57
references.pmid: 19190116
references.citation: Nat Med. 2011 Mar;17(3):320-9
references.pmid: 21383745
references.citation: Mar Drugs. 2014 Jan 27;12(2):719-33
references.pmid: 24473171
references.citation: Oncogene. 2014 Oct 30;33(44):5201-10
references.pmid: 24213580
references.citation: Nat Med. 2001 Aug;7(8):961-6
references.pmid: 11479630
references.citation: Int J Cancer. 2001 May 15;92(4):583-8
references.pmid: 11304695
references.citation: Eur J Cancer. 2007 Aug;43(12):1791-801
references.pmid: 17588740
references.citation: Cancer Res. 2010 Mar 15;70(6):2235-44
references.pmid: 20215499
references.citation: J Clin Invest. 2012 Mar;122(3):886-98
references.pmid: 22293175
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6775-9
references.pmid: 10841572
references.citation: Adv Exp Med Biol. 2001;500:289-99
references.pmid: 11764956
references.citation: Cancer Res. 2002 Jun 15;62(12):3377-81
references.pmid: 12067978
references.citation: Nucleic Acids Res. 2011 Oct;39(18):8248-57
references.pmid: 21727089
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6449-55
references.pmid: 18927284
references.citation: Cell. 2010 Apr 2;141(1):39-51
references.pmid: 20371344
references.citation: Gynecol Oncol. 2011 Dec;123(3):553-6
references.pmid: 21917307
references.citation: Chem Biol. 2011 Aug 26;18(8):988-99
references.pmid: 21867914
references.citation: Eur J Cancer. 2011 May;47(7):1006-12
references.pmid: 21376569
references.citation: Expert Rev Anticancer Ther. 2013 Jun;13(6 Suppl 1):21-4
references.pmid: 23638727
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7
references.pmid: 17656556
references.citation: Cancer Cell. 2013 Feb 11;23(2):249-62
references.pmid: 23410977
references.citation: Pharmacol Ther. 2013 Feb;137(2):216-24
references.pmid: 23085431
references.citation: Cancer Res. 2005 Apr 1;65(7):2964-71
references.pmid: 15805300
references.citation: Med Oncol. 2013 Mar;30(1):435
references.pmid: 23397080
references.citation: Clin Cancer Res. 2014 Mar 1;20(5):1190-203
references.pmid: 24277455
references.citation: Trends Immunol. 2002 Nov;23(11):549-55
references.pmid: 12401408
references.citation: Nat Prod Rep. 2009 Mar;26(3):322-37
references.pmid: 19240944
references.citation: Clin Exp Immunol. 2012 Feb;167(2):195-205
references.pmid: 22235995
references.citation: Int J Cancer. 2013 Nov;133(9):2024-33
references.pmid: 23588839
references.citation: Gynecol Oncol. 2012 Jan;124(1):48-52
references.pmid: 21996263
references.citation: Neoplasia. 2011 Feb;13(2):145-53
references.pmid: 21403840
references.citation: Invest New Drugs. 2010 Aug;28(4):529-30
references.pmid: 19430728
references.citation: Lancet Oncol. 2007 Jul;8(7):595-602
references.pmid: 17586092
references.citation: Cancer Res. 2006 Aug 15;66(16):8155-62
references.pmid: 16912194
references.citation: Mol Cancer Ther. 2010 Aug;9(8):2157-63
references.pmid: 20647340
references.citation: Nat Rev Cancer. 2004 Jan;4(1):71-8
references.pmid: 14708027
references.citation: Eur J Cancer. 2008 Mar;44(4):609-18
references.pmid: 18243687
references.citation: Expert Rev Anticancer Ther. 2013 Jun;13(6 Suppl 1):11-9
references.pmid: 23638726